Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CC-chemokine receptor 3 antagonists - Millennium/Roche Bioscience

Drug Profile

Research programme: CC-chemokine receptor 3 antagonists - Millennium/Roche Bioscience

Alternative Names: CCR3 antagonists research programme - Millennium/Roche Bioscience

Latest Information Update: 23 Aug 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Millennium Pharmaceuticals; Roche Palo Alto LLC
  • Class
  • Mechanism of Action CCR3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Asthma; Hypersensitivity

Most Recent Events

  • 26 Jan 2000 LeukoSite has been merged into Millennium Pharmaceuticals
  • 05 Jun 1998 New profile
  • 05 Jun 1998 Preclinical development for Allergy in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top